Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
← catalyst calendarNCT07291037 · readout in 894 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
205
Countries
Australia, Austria, Belgium +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-31 | actual | When the study began enrolling |
| Primary completion | 2029-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Datopotamab deruxtecan (Dato-DXd) — also filed as DS-1062a
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Approximately 2.5 years
Overall survival (OS)
measured Approximately 3.5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed